Human Cathepsin B / CTSB Protein, His Tag (MALS verified)
分子別名（Synonym）
CTSB,CPSB,APPS
表達區(qū)間及表達系統(tǒng)（Source）
Human Cathepsin B, His Tag (CTB-H5222) is expressed from human 293 cells (HEK293). It contains AA Arg 18 - Ile 339 (Accession # P07858-1 (L26V)).
Predicted N-terminus: Arg 18 & Leu 80
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus. The Human Cathepsin B will be further processed into mature form (Leu 80-Ile 339). The protein has a calculated MW of 36.7 kDa (pro-form) and 29.5 kDa (mature-form). The protein migrates as 30-32 kDa and 38-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
組織蛋白酶B（CTSB）亦稱APP分泌酶（APPS）及CPSB，屬肽酶C1家族酶蛋白。該酶以前酶原形式合成，經(jīng)信號肽切除后，無活性的酶原經(jīng)修飾（包括前結(jié)構(gòu)域切除）轉(zhuǎn)化為活性酶。其催化活性包括：廣譜水解多肽鍵；特異性切割小分子底物中的-Arg-Arg-|-Xaa鍵（此特性區(qū)別于組織蛋白酶L）；除內(nèi)肽酶活性外，還具有肽酰二肽酶活性，可釋放C端二肽。作為巰基蛋白酶，CTSB/CPSB參與細胞內(nèi)蛋白質(zhì)降解與代謝更新，并在腫瘤侵襲轉(zhuǎn)移中發(fā)揮重要作用。該酶過表達與食管腺癌等多種腫瘤的發(fā)生發(fā)展密切相關。
關鍵字： Cathepsin B;Cathepsin B蛋白;CTSB重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。